Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Synovial biopsies in inflammatory arthritis: precision medicine in rheumatoid arthritis.

Small A, Wechalekar MD.

Expert Rev Mol Diagn. 2020 Mar;20(3):315-325. doi: 10.1080/14737159.2020.1707671. Epub 2020 Jan 7.

PMID:
31865803
2.

The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis.

Wechalekar MD, Najm A, Veale DJ, Strand V.

J Rheumatol. 2019 Oct;46(10):1365-1368. doi: 10.3899/jrheum.181062. Epub 2019 Jan 15.

PMID:
30647173
3.

Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, de Bellefon LM, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 19;20(1):282. doi: 10.1186/s13075-018-1795-5.

4.

Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, Meric de Bellefon L, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 3;20(1):265. doi: 10.1186/s13075-018-1762-1. Erratum in: Arthritis Res Ther. 2018 Dec 19;20(1):282.

5.

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.

Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, Veale DJ, Fearon U, Pitzalis C, Humby F, Bombardieri M, Axel A, Adams H 3rd, Chiu C, Sharp M, Alvarez J, Anderson I, Madakamutil L, Nagpal S, Guo Y.

Arthritis Res Ther. 2018 May 2;20(1):85. doi: 10.1186/s13075-018-1578-z.

6.

Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.

Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, Scott B, Loza M, Orr C, McGarry T, Bombardieri M, Humby F, Proudman SM, Pitzalis C, Smith MD, Friedman JR, Anderson I, Madakamutil L, Veale DJ, Fearon U, Nagpal S.

PLoS One. 2018 Feb 28;13(2):e0192704. doi: 10.1371/journal.pone.0192704. eCollection 2018.

7.

PD‑1+ T cells contribute differently to the pathogenesis of rheumatoid arthritis and psoriatic arthritis.

Murray-Brown W, Wechalekar MD, Smith M.

Pol Arch Intern Med. 2017 Dec 22;127(12):813-814. doi: 10.20452/pamw.4172. Epub 2017 Dec 21. No abstract available.

8.

Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.

Wabe N, Wojciechowski J, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Proudman S, Wiese MD.

Int J Rheum Dis. 2017 Oct;20(10):1447-1456. doi: 10.1111/1756-185X.13184. Epub 2017 Sep 26.

PMID:
28952204
9.

Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.

Walsh AM, Wechalekar MD, Guo Y, Yin X, Weedon H, Proudman SM, Smith MD, Nagpal S.

PLoS One. 2017 Sep 1;12(9):e0183928. doi: 10.1371/journal.pone.0183928. eCollection 2017.

10.

Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro.

Dharmapatni AASSK, Algate K, Coleman R, Lorimer M, Cantley MD, Smith MD, Wechalekar MD, Crotti TN.

Inflammation. 2017 Oct;40(5):1566-1575. doi: 10.1007/s10753-017-0597-2.

PMID:
28555364
11.

CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression.

Guo Y, Walsh AM, Fearon U, Smith MD, Wechalekar MD, Yin X, Cole S, Orr C, McGarry T, Canavan M, Kelly S, Lin TA, Liu X, Proudman SM, Veale DJ, Pitzalis C, Nagpal S.

J Immunol. 2017 Jun 1;198(11):4490-4501. doi: 10.4049/jimmunol.1601988. Epub 2017 Apr 28.

12.

A Treat-to-Target Strategy Preserves Work Capacity in a Rheumatoid Arthritis Inception Cohort Treated With Combination Conventional DMARD Therapy.

Wechalekar MD, Quinn S, Lester S, Metcalf RG, Shanahan E, Walker JG, Smith MD, Hill CL, Shanahan EM, Proudman SM.

J Clin Rheumatol. 2017 Apr;23(3):131-137. doi: 10.1097/RHU.0000000000000506.

PMID:
28277345
13.

Arthroscopic guided synovial biopsy in rheumatology: current perspectives.

Wechalekar MD, Smith MD.

Int J Rheum Dis. 2017 Feb;20(2):141-144. doi: 10.1111/1756-185X.13020. Epub 2016 Dec 19. Review.

PMID:
27990762
14.

Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission.

Wechalekar MD, Lester S, Hill CL, Lee A, Rischmueller M, Smith MD, Walker JG, Proudman SM.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1616-1623. doi: 10.1002/acr.22887.

15.

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.

Wabe NT, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee AT, Spargo LD, Metcalf RG, Hall C, Proudman SM, Wiese MD.

J Rheumatol. 2016 Sep;43(9):1643-9. doi: 10.3899/jrheum.151392. Epub 2016 Jul 15.

PMID:
27422892
16.

Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Hall C, Spargo L, Metcalf R, Proudman SM, Wiese MD.

Int J Clin Pract. 2016 Apr;70(4):340-50. doi: 10.1111/ijcp.12785. Epub 2016 Mar 14.

PMID:
26987888
17.

Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf R, Hall C, Proudman SM, Wiese MD.

Int J Rheum Dis. 2017 May;20(5):576-583. doi: 10.1111/1756-185X.12816. Epub 2015 Dec 22.

PMID:
26692459
18.

Nonsteroidal anti-inflammatory drugs for treatment of acute gout.

van Durme CM, Wechalekar MD, Landewé RB.

JAMA. 2015 Jun 9;313(22):2276-7. doi: 10.1001/jama.2015.1881.

PMID:
26057289
19.

Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf RG, Hall C, Proudman SM, Wiese MD.

Arthritis Res Ther. 2015 Mar 8;17:48. doi: 10.1186/s13075-015-0562-0.

20.

Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative.

Graf SW, Whittle SL, Wechalekar MD, Moi JH, Barrett C, Hill CL, Littlejohn G, Lynch N, Major G, Taylor AL, Buchbinder R, Zochling J.

Int J Rheum Dis. 2015 Mar;18(3):341-51. doi: 10.1111/1756-185X.12557. Epub 2015 Apr 17. Review.

PMID:
25884565
21.

Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states.

Wechalekar MD, Smith MD.

World J Orthop. 2014 Nov 18;5(5):566-73. doi: 10.5312/wjo.v5.i5.566. eCollection 2014 Nov 18. Review.

22.

Multicentric myofibroblastic sarcoma.

Wechalekar MD, Ayres O, Farshid G, Clayer M, Cleland LG.

BMJ Case Rep. 2014 Nov 3;2014. pii: bcr2013201666. doi: 10.1136/bcr-2013-201666.

23.

Non-steroidal anti-inflammatory drugs for acute gout.

van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB.

Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/14651858.CD010120.pub2. Review.

PMID:
25225849
24.

Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review.

Vinik O, Wechalekar MD, Falzon L, Buchbinder R, van der Heijde DM, Bombardier C.

J Rheumatol Suppl. 2014 Sep;92:70-4. doi: 10.3899/jrheum.140465. Review.

PMID:
25180131
25.

The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors.

Wechalekar MD, Vinik O, Moi JH, Sivera F, van Echteld IA, van Durme C, Falzon L, Bombardier C, Carmona L, Aletaha D, Landewé RB, van der Heijde DM, Buchbinder R.

J Rheumatol Suppl. 2014 Sep;92:15-25. doi: 10.3899/jrheum.140458. Review.

PMID:
25180124
26.

Interleukin-1 inhibitors for acute gout.

Sivera F, Wechalekar MD, Andrés M, Buchbinder R, Carmona L.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009993. doi: 10.1002/14651858.CD009993.pub2. Review.

PMID:
25177840
27.

Colchicine for acute gout.

van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D.

Cochrane Database Syst Rev. 2014 Aug 15;(8):CD006190. doi: 10.1002/14651858.CD006190.pub2. Review.

PMID:
25123076
28.

Th17 and Th22 cells in psoriatic arthritis and psoriasis.

Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R, Gaston H.

Arthritis Res Ther. 2013 Sep 26;15(5):R136. doi: 10.1186/ar4317.

29.

Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.

Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG.

Ann Rheum Dis. 2015 Jan;74(1):89-95. doi: 10.1136/annrheumdis-2013-204145. Epub 2013 Sep 30.

PMID:
24081439
30.

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.

Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewé RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Müller-Ladner U, Ostergaard M, Zochling J, Falzon L, van der Heijde DM.

Ann Rheum Dis. 2014 Feb;73(2):328-35. doi: 10.1136/annrheumdis-2013-203325. Epub 2013 Jul 18.

31.

Intra-articular glucocorticoids for acute gout.

Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009920. doi: 10.1002/14651858.CD009920.pub2. Review.

PMID:
23633379
32.

Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.

Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueller M, Hill CL.

Arthritis Rheum. 2012 May;64(5):1316-22. doi: 10.1002/art.33506.

33.

Esophageal adenocarcinoma and hypertrophic osteoarthropathy with improvement following resection of esophageal cancer.

Wechalekar MD, Kennedy NA, Ahern M, Slavotinek J, Smith MD.

J Clin Rheumatol. 2011 Sep;17(6):323-4. doi: 10.1097/RHU.0b013e31822e0642.

PMID:
21869707
34.

Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab.

Wechalekar MD, Rischmueller M, Whittle S, Burnet S, Hill CL.

J Clin Rheumatol. 2010 Mar;16(2):79-80. doi: 10.1097/RHU.0b013e3181d06f70.

PMID:
20216128
35.

Achalasia cardia presenting as stridor.

Wechalekar MD, Southcott AM.

Respirology. 2008 Nov;13(7):1088-90. doi: 10.1111/j.1440-1843.2008.01395.x. Epub 2008 Sep 10.

PMID:
18785914
36.

Hereditary elliptocytosis with hemolytic anaemia (a study of genetic markers).

Grover S, Baxi AJ, Wechalekar MD, Lakhe RT, Parande CM.

J Assoc Physicians India. 1977 Apr;25(4):293-8. No abstract available.

PMID:
914761
37.

Screening tests in hypertriglyceridemia thalassemia syndrome.

Parande CM, Wechalekar MD, Bhai I, Parande AS, Jaiswal RB.

Indian Pediatr. 1975 Jul;12(7):593-8. No abstract available.

PMID:
1184161
38.

"Male turner": clinical findings and chromosomal analysis in three phenotypic males.

Sonwalkar A, Grover S, Chaubey BS, Sonwalkar AV, Wechalekar MD, Rawat MS.

J Postgrad Med. 1975 Apr;21(2):96-100. No abstract available.

PMID:
1177172
39.

Hypertriglyceridemia-thalassemia syndrome.

Jaiswal RB, Bhai I, Parande AS, Wechalekar MD, Nath MC.

Indian Pediatr. 1974 May;11(5):385-9. No abstract available.

PMID:
4426667
40.

A new approach for refractory oedema--pharmacological paracentesis.

Sonwalkar AV, Wechalekar MD, Wechalekar DK, Waikar SM, Bhala BB.

J Assoc Physicians India. 1973 Jul;21(7):585-8. No abstract available.

PMID:
4283774
41.

Epidemic dropsy in Chandrapur (Maharashtra) (epidemiological and clinical study).

Sainani GS, Rajkondawar VL, Wechalekar MD, Wechalekar DK.

J Assoc Physicians India. 1972 Apr;20(4):301-6. No abstract available.

PMID:
5026518
42.

A clinical study of bundle branch block--with special reference to bilateral bundle branch block.

Sainani GS, Wechalekar DK, Wechalekar MD.

J Assoc Physicians India. 1972 Jan;20(1):13-8. No abstract available.

PMID:
5025978

Supplemental Content

Loading ...
Support Center